share_log

Cantor Fitzgerald Reiterates Overweight on Sanara MedTech, Maintains $59 Price Target

Cantor Fitzgerald Reiterates Overweight on Sanara MedTech, Maintains $59 Price Target

坎托·菲茨杰拉德重申增持Sanara MedTech,维持59美元的目标股价
Benzinga ·  2023/08/17 11:47

Cantor Fitzgerald analyst Brandon Folkes reiterates Sanara MedTech (NASDAQ:SMTI) with a Overweight and maintains $59 price target.

Cantor Fitzgerald分析师布兰登·福克斯重申,Sanara MedTech(纳斯达克:SMTI)增持,维持59美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发